A sort of new research Non-invasive, artificial intelligence-enabled coronary computed tomography angiography was found to be effective at identifying stenoses compared to the traditional echocardiographic gold standard and other more invasive methods of detecting heart disease.
A product made by New York-based New York-based company Cleerly was found to accurately identify plaque buildup in coronary arteries. Its goal is to create a paradigm in which heart disease is detected early, rather than when patients start showing symptoms.
AI-based assessment matches or exceeds core laboratory quantitative coronary angiography (QCA), core laboratory interpreted coronary computed tomography angiography (CTA), and invasive fractional flow reserve (FFR) to assess coronary CTA stenosis severity ability, according to learning. The study noted that, in addition to its strong efficacy, AI technology also has a faster turnaround time compared to traditional methods.
“cleanCleerly’s CEO and founder James Min said in an email that the company’s non-invasive platform is highly accurate compared to invasive coronary angiography (ICA) and is comparable to invasive fractional flow reserve (FFR). ) is more consistent. “These results establish cleanThe technology platform is the most accurate technology platform to quantify and characterize coronary atherosclerosis and vascular morphology to date. “
He added that given that fewer than 3,000 board-certified physician readers are able to interpret coronary CT angiography, Cleary’s Technology “There is now a unique opportunity for all health systems and providers to conduct a comprehensive analysis of CCTA in a way that cannot be accomplished with human interpretation alone.” [Click image to enlarge.]
Cleerly’s technology works by identifying atherosclerosis, the buildup of plaque in the arteries of the heart. It then completes a comprehensive assessment, covering every coronary branch and artery, and finds, characterizes, and assesses plaque buildup. Cleerly hopes its assessment will allow doctors to assess a patient’s risk of a heart attack.
According to Min, many heart attack patients were identified as low-risk prior to their attack and had no symptoms prior to their attack. Atherosclerotic plaques that do not reduce blood flow in the arteries of the heart can cause attacks when the patient is not showing symptoms. Therefore, traditional methods miss these patients and do not label them with heart disease. With a focus on atherosclerosis, Cleerly hopes its technology will be able to identify these patients.
“ClearlyOur approach goes beyond current approaches from treating late symptoms to assessing the entire continuum of cardiac manifestations, focusing on the assessment of patients previously missed by traditional approaches, where it is easier to proactively identify cardiac progression in the early stages when we can prevent it. ,” said Min.cleanAn accurate diagnostic approach to better capture at-risk patients and, for the first time, a personalized pathway to tailor treatment and disease tracking over time. This approach to precision cardiac care improves clinical outcomes while providing significant cost savings. “
Historically, symptoms have often driven cardiac care, according to Min.
“Our historical approach emphasizes late-stage symptom-driven care, which is analogous to starting treatment of cancer patients when metastases have already developed. In contrast, an early-stage proactive paradigm of treating actual heart disease (atherosclerosis) in a personalized way can fundamentally Shift the nursing paradigm toward the goal of eliminating heart attacks,” Min said.
The results of this study are the second in a series of six Evaluating the efficacy of Cleerly compared to Cleerly
Photo: Narongrit Doungmanee, Getty Images; Image: JACC Journal
